OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Eradat on the Unmet Needs in CLL

September 19th 2019

Herbert A. Eradat, MD, associate professor, University of California, Los Angeles Medical Center, discusses unmet needs in chronic lymphocytic leukemia.

Dr. Gunderson on the GOG-252 Trial in Advanced Ovarian Cancer

September 19th 2019

Camille C. Gunderson, MD, discusses the phase III open-label GOG-252 trial in advanced ovarian cancer.

Dr. Jonasch on Utilizing the Tumor Microenvironment and Epigenetics as Biomarkers in RCC

September 19th 2019

Eric Jonasch, MD, on how understanding features within the tumor microenvironment and mutated epigenetic modifying genes may provide insight on prognosis or treatment strategies in renal cell carcinoma.

Dr. Welslau on the Rationale for the REFLECT Trial in DLBCL

September 19th 2019

Manfred Welslau, MD, Internal Medicine, Hematology and Oncology, Onkologie Aschaffenburg, discusses the rationale for the REFLECT trial in diffuse large B-cell lymphoma.

Dr. Geyer on Challenges in HER2+ Metastatic Breast Cancer Management

September 19th 2019

Charles E. Geyer, Jr, MD, professor of medicine, Virginia Commonwealth University School of Medicine; associate director for clinical research and Harrigan, Haw, Luck Families chair in Cancer Research, Massey Cancer Center, discusses ongoing challenges in the management of patients with metastatic HER2-positive breast cancer.

Dr. Moore on Research Evaluating Repeat Exposure to PARP Inhibition in Ovarian Cancer

September 19th 2019

Kathleen Moore, MD, director, Oklahoma TSET Phase I Program, and associate professor, Section of Gynecologic Oncology, Stephenson Cancer Center, discusses research evaluating repeat exposure to PARP inhibition in patients with platinum-sensitive ovarian cancer.

Dr. Cohen on Eligibility for Ablation Therapy in Liver Cancer

September 19th 2019

Emil Israel Cohen, MD, an assistant professor at Medstar Georgetown University Hospital, discusses the criteria for ablation therapy in patients with liver cancer.

Dr. Nathan on Long-Term Outcomes With Dabrafenib/Trametinib in BRAF V600-Mutant Melanoma

September 19th 2019

Paul D. Nathan, MBBS, PhD, FRCP, consultant medical oncologist, Mount Vernon Cancer Centre, discusses the long-term outcomes with the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with BRAF V600-mutant unresectable or metastatic melanoma.

Dr. Richards on PARP Inhibition in Pancreatic Cancer

September 19th 2019

Donald A. Richards, MD, PhD, medical oncologist, Texas Oncology, discusses PARP inhibition in patients with pancreatic cancer.

Dr. Patel on Choosing Immunotherapy Drugs for NSCLC

September 19th 2019

Manish R. Patel, DO, discusses choosing immunotherapy drugs for patients with non–small cell lung cancer.

Dr. Lyman on Rituximab Biosimilars in Non-Hodgkin Lymphoma

September 19th 2019

Gary H. Lyman, MD, MPH, senior lead, Health Care Quality and Policy, Hutchinson Institute for Cancer Outcomes Research, member, Cancer Prevention Program, Public Health Services Division, and member, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the use of rituximab (Rituxan) biosimilars in the treatment of patients with non-Hodgkin lymphoma (NHL).

Dr. Henske Discusses a Pathway Deficiency in Chromophobe RCC

September 18th 2019

Elizabeth Petri Henske, MD, director of the Center for LAM Research and Clinical Care, co-director of the Pulmonary Genetics Center at Brigham and Women’s Hospital, and professor at Harvard Medical School, discusses a newly discovered pathway in chromophobe renal cell carcinoma.

Dr. George on the Use of Radium-223 in Prostate Cancer

September 18th 2019

Daniel J. George, MD, professor of medicine and surgery, member, Duke Cancer Institute, discusses the use of radium-223 dichloride (Xofigo) in prostate cancer.

Dr. Zelenetz on Anticipated Research in MCL

September 18th 2019

Andrew D. Zelenetz, MD, PhD, medical director of Quality Informatics at Memorial Sloan Kettering Cancer Center, discusses anticipated research in mantle cell lymphoma (MCL).

Dr. Seet on Aspects of Treatment Discontinuation in CML

September 18th 2019

Christopher S. Seet, MD, PhD, hematologist and oncologist, UCLA, discusses aspects of treatment discontinuation in chronic myeloid leukemia (CML).

Dr. Grivas on Biomarker for Pembrolizumab Response in Urothelial Cancer

September 18th 2019

Petros Grivas, MD, discusses searching for biomarkers in patients with urothelial cancer to indicate response to pembrolizumab in the KEYNOTE-052 trial.

Dr. Manji on Treatment for NTRK Fusion+ CRC

September 18th 2019

Gulam A. Manji, MD, PhD, discusses treatment for patients with colorectal cancer who harbor NTRK fusions.

Dr. Santomasso on Managing CNS Toxicity from CAR T-Cell Therapy for B-Cell Lymphoma

September 17th 2019

Bianca D. Santomasso, MD, PhD, discusses how she prevents central nervous system toxicity due to CAR T-cell therapy for aggressive B-cell lymphoma in her own practice.

Dr. Rule on Searching for a Biomarker Indicating Indolent MCL

September 17th 2019

Simon Rule, MD, discusses a study comparing patients with newly diagnosed mantle cell lymphoma who receive immediate systemic treatment immediately versus patients who are closely monitored instead.

Dr. McGregor on Choosing Combo Regimens in Advanced RCC

September 16th 2019

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses how to choose between combination treatments in advanced renal cell carcinoma.